Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogens
First Claim
Patent Images
1. A purified nucleic acid molecule selected from the group consisting of SEQ ID NOS:
- 7, 8, 9, 10, and 11.
4 Assignments
0 Petitions
Accused Products
Abstract
A method of preventing or inhibiting infection by a parasite or virus in vivo comprises administering to a human in need thereof a parasite or virus mitogen in a sub-mitogenic amount sufficient to induce a protective immune response against the parasite or virus in the human.
1 Citation
78 Claims
- 1. A purified nucleic acid molecule selected from the group consisting of SEQ ID NOS:
-
2. A purified nucleic acid molecule encoding a peptide selected from the group consisting of of SEQ ID NOS:
- 1, 2, 3, and 4.
-
5. A purified nucleic acid molecule degenerate from SEQ ID NOS:
- 7, 8, 9, 10, and 11 as a result of this genetic code.
- 6. A purified nucleic acid molecule, which encodes Tc45 polypeptide, an allelic variant of Tc45 polypeptide, or a homolog of Tc45 polypeptide.
- 17. A purified eukaryotic amino acid racemase having a 38 kd to 45 kda more or less 10%.
-
33. The plasmid deposited at CNCM under the Accession Number I-2221 or I-2344.
-
34. An immunological complex comprising a Tc45 polypeptide and an antibody that specifically recognizes said polypeptide.
- 40. A purified polynucleotide encoding an eukaryotic protein with an amino acid racemase activity.
-
41. A purified polynucleotide encoding an eukaryotic protein with a proline racemase activity.
-
42. A polynucleotide encoding an eukaryotic protein, which is recognized by antibodies raised against an eukaryotic protein having an amino acid racemase activity such as a proline racemase.
- 48. A purified eukaryotic protein with an amino acid racemase activity such as a proline racemase.
-
59. A process for screening a molecule capable of inhibiting the amino acid racemase activity of an eukaryotic protein comprising the steps of:
-
contacting the purified eukaryotic racemase protein with standard doses of a molecule to be tested;
measuring inhibition of racemase activity; and
selecting the molecule.
-
- 60. A method of inhibiting an eukaryotic protein with an amino acid racemase activity, which comprises treating a patient by administering an effective amount of a molecule that inhibits said eukaryotic protein.
-
62. A method for producing an eukaryotic recombinant amino acid racemase comprising the following steps:
-
(a) culturing a bacterial or a eukaryotic host harboring an over expression system including an insert containing a polynucleotide sequence encoding an eukaryotic amino acid racemase;
(b) separating the recombinant eukaryotic amino acid racemase from the host proteins; and
(c) purifying the eukaryotic amino acid racemase. - View Dependent Claims (63, 64)
-
-
65. A method for the production of D-amino acid using a purified eukaryotic amino acid racemase comprising the steps of:
-
(a) incubating L-amino acid with the recombinant eukaryotic amino acid racemase;
(b) separating the D-amino acid produced in step a; and
(c) purifying the D-amino acid.
-
- 66. A method of preventing or inhibiting infection by a virus in vivo, wherein the method comprises administering to a subject in need thereof a virus mitogen in a sub-mitogenic amount sufficient to induce a protective immune response against the virus in the subject.
- 69. A method of preventing or inhibiting infection by a protozoan parasite in vivo, wherein the method comprises administering to a human in need thereof a protozoan parasite mitogen in a sub-mitogenic amount sufficient to induce a protective immune response against the protozoan parasite in the human.
-
73. Any molecular modification of the gene or a fragment of the gene encoding for a racemase/mitogen that leads to the inhibition of the expression of the protein by the parasite or virus (gene knock out), and further utilization of parasites or viruses lacking those activities in vivo aiming at immunoprotective responses.
-
74. Any molecular modification of the gene or a fragment of the gene encoding for a racemase/mitogen that leads to the hyperexpression of the protein by the parasite or virus (gene transgenesis), and further utilization of the parasite or virus to produce high amounts of the protein aiming at producing high amounts of the native protein.
-
75. Any molecular modification of the gene or a fragment of the gene encoding for a racemase/mitogen that leads to an attenuation of parasite or virus infectivity, or interaction with a host cell, and further injection of the parasites or viruses in vivo aiming at immunoprotective responses.
-
76. Any molecular modification (for instance directed mutagenesis) of the protein or of its active site that leads to the inhibition of its enzymatic or its mitogenic activity and further injection of mutated parasites or viruses in vivo aiming at immunoprotective responses.
-
77. Use of any molecular or biochemical modification of the enzymatic activity of the racemase (inhibition of the active site) aiming at developing specific immunotherapy.
-
78. Any molecule or compound that inhibits the enzymatic activity of the protein aiming at developing a drug against parasite or virus infection or specific treatment of parasitic or viral disease.
Specification